Table 1 Effects of treatments on metabolic and cardiovascular outcome in rheumatoid arthritis patients
From: The interplay between inflammation and metabolism in rheumatoid arthritis
Drug | Conditions and purpose | Biological targets | Phase | Status | ClinicalTrials.gov identifiers |
|---|---|---|---|---|---|
Celecoxib in comparison with Naproxen and Ibuprofen | CV safety in patients with/at high risk for CV diseases | COX | IV | Active, not recruiting | NCT00346216 |
HCQ | Improvement in the insulin sensitivity | Antigen processing in APC | III | Completed | NCT01132118 |
Anti-TNF-α agents in comparison with triple therapy (SSZ+MTX+HCQ) | Improvement in the myocardial structure and function | TNF-α (others) | --- | Recruiting participants | NCT01548768 |
Adalimumab | Impact on brachial ED and large artery stiffness | TNF-α | III | Recruiting participants | NCT01954381 |
Adalimumab or Infliximab or Etanercept | Development, deterioration or improvement in subclinical heart dysfunction | TNF-α | IV | Unknown | NCT01072058 |
Adalimumab or Infliximab or Etanercept or Certolizumab | Effects on blood pressure and ED | TNF-α | IV | Recruiting | NCT02132234 |
Tocilizumab | Improvement in markers of both ED and disease activity/inflammation | IL-6 | IV | Unknown | NCT01752335 |
Tocilizumab (in comparison with MTX) | Improvement in the lipids, arterial stiffness, and markers of atherogenic risk | IL-6 (dihydrofolate reductase) | III | Completed | NCT00535782 |
Tocilizumab(in comparison with Etanercept) | Effects on the rate of CV ischemic events | IL-6 (TNF-α) | IV | Active, not recruiting | NCT01331837 |
Tasocitinib | Improvement in cholesterol metabolism | JAK | I | Completed | NCT01262118 |
Anakinra | Lowering HbA1c as well as changes in disease activity in RA patients with T2DM | IL-1 | IV | Recruiting participants | NCT02236481 |
